StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.8.3
  1. Startseite
  2. /Verbindung

Doxofyllin

Doxofylline

HCID 50942
Neue Reaktion
Drucken

Daten werden ergänzt – lade die Seite später neu, um den aktuellen Stand zu sehen

GrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
TeilstruktursucheÄhnliche Strukturen suchen

Grundinformationen

CAS
69975-86-6
Standard-SMILES
Cn1c(=O)c2c(ncn2CC2OCCO2)n(C)c1=O
InChIKey
HWXIGFIVGWUZAO-UHFFFAOYSA-N
Summenformel
C11H14N4O4
Durchschnittliche Molmasse
266,25 g/mol
Monoisotopische Masse
266,10150494

Überblick

Doxofylline is an oxopurine that is a derivative of xanthine, methylated at N-1 and N-3 and carrying a 1,3-dioxolan-2-ylmethyl group at N-7, used in the treatment of asthma. It has a role as a bronchodilator agent, an anti-asthmatic drug and an antitussive. It is functionally related to a 7H-xanthine.

Namen und Bezeichner

Bevorzugter Name
Doxofylline
IUPAC
7-(1,3-dioxolan-2-ylmethyl)-1,3-dimethylpurine-2,6-dione
Lokaler Name
Doxofyllin
Englischer Name
Doxofylline
Summenformel
C11H14N4O4
Molmasse
266.25

Namen und Synonyme

DOXOFYLLINE69975-86-6DoxophyllineDioxyfillineAnsimarVentaxDoxofilinaDoxofyllinumSynasmaABC 12/37-(1,3-Dioxolan-2-ylmethyl)theophyllineDTXSID7022968
Weitere Namen anzeigen
abc12/3AnsirnarMAXIVENTABC 1213DoxofyliineDoxof3rlline
ABC-12/3MPM23GMO7ZNSC-7596451H-Purine-2,6-dione, 7-(1,3-dioxolan-2-ylmethyl)-3,7-dihydro-1,3-dimethyl-CHEBI:94714DTXCID002968TMDO7-[(1,3-dioxolan-2-yl)methyl]-1,3-dimethyl-2,3,6,7-tetrahydro-1H-purine-2,6-dione

Datenbank-Bezeichner

CAS
69975-86-6
PubChem CID
50942
DTXSID
DTXSID7022968
ChEMBL
CHEMBL1527608
ChEBI
CHEBI:94714
UNII
MPM23GMO7Z
EC Number
274-239-6
Nikkaji
J23.295E

Eigenschaften

Berechnete StruktureigenschaftenWird ergänzt

XLogP
-0,9
Polarare Oberfläche (TPSA)
76,9 Ų
H-Brücken-Donoren
0
H-Brücken-Akzeptoren
5
Frei drehbare Bindungen
2
Schwere Atome
19
Formalladung
0
Komplexität
398

Experimentelle und physikochemische Eigenschaften

Drugs · 2 Einträge

Pharmaceuticals -> Listed in ZINC15

Pharmaceuticals -> Brochodilators

Solubility · 2 Einträge

Insoluble

>39.9 [ug/mL] (The mean of the results at pH 7.4)

Physikochemische Eigenschaften

Schmelzpunkt
144 · 144-146°C
Siedepunkt
409.46 °C · 409.46°C (rough estimate)
Dichte
1.2896 · 1.2896 (rough estimate)
Brechungsindex
1.6 · 1.6000 (estimate)
storage temp.
2 · under inert gas (nitrogen or Argon) at 2-8°C
Löslichkeit
DMSO (Slightly), Methanol (Slightly)
Aggregatzustand
Solid
pka
0.42 · 0.42±0.70(Predicted)
Farbe
White to Off-White

Sicherheit und Regulatorisches

Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.

GHS-Klassifizierung

GHS Classification · 4 Einträge

Warning

H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]

P264, P264+P265, P270, P280, P301+P317, P302+P352, P305+P351+P338, P321, P330, P332+P317, P337+P317, P362+P364, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 3 reports by companies from 2 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Gefahrenhinweise

Hazard Classes and CategoriesAcute Tox. 4 (100%)

Sicherheitsdaten

hs_code
29399990
risk_code
36/37/38
Toxizität
LD50 in mice (mg/kg): 841 orally; 215.6 i.v.; in rats: 1022.4 orally, 445 i.p. (Franzone)
hazard_code
Xi
safety_code
26-36/37

Chemie und Industrie

Pharmakologische Informationen

ATC Code · 2 Einträge

R - Respiratory system

QR - Respiratory system

Protein BindingAt pH 7.4, the fraction of plasma protein binding is about 48%.
Pharmacodynamics · 1 Eintrag

Doxofylline is a methylxanthine bronchodilator with potent bronchodilator activity comparable to that of theophylline. In animal studies, doxofylline demonstrated to attenuate bronchoconstriction, inflammatory actions and the release of thromboxane A2 (TXA2) when challenged with platelet-activating factor. Doxofylline does not demonstrate direct inhibition of any histone deacetylase (HDAC) enzymes or known PDE enzyme isoforms and did not act as an antagonist at A2 or A2 receptors. The affinity for adenosine A1, A2A and A2B receptors are reported to be all higher than 100 µM. It only displays an inhibitory action against PDE2A1 and antagonism at adenosine A(2A) at high concentrations. A study demonstrated that doxofylline interacts with β2-adrenoceptors to induce blood vessel relaxation and airway smooth muscle relaxation. In dog studies, doxofylline decreased airway responsiveness at a dose that did not affect heart rate and respiratory rate.

Mechanism of Action · 1 Eintrag

The main mechanism of action of doxofylline is unclear. One of the mechanisms of action of is thought to arise from the inhibition of phosphodiesterase activity thus increasing the levels of cAMP and promoting smooth muscle relaxation. The interaction of doxofylline with beta-2 adrenoceptors was demonstrated by a study using nonlinear chromatography, frontal analysis and molecular docking. Serine 169 and serine 173 residues in the receptor are thought to be critical binding sites for doxofylline where hydrogen bonds are formed. Via mediating the actions of beta-2 adrenoceptors, doxofylline induces blood vessel relaxation and airway smooth muscle relaxation. There is also evidence that doxofylline may exert anti-inflammatory actions by reducing the pleurisy induced by the inflammatory mediator platelet activating factor (PAF) according to a rat study. It is suggested that doxofylline may play an important role in attenuating leukocyte diapedesis, supported by mouse preclinical studies where doxofylline administration was associated with inhibited leukocyte migration across vascular endothelial cells in vivo and in vitro.Unlike theophylline, doxofylline does not inhibit tumor necrosis factor-induced interleukin (IL)-8 secretion in ASM cells.

Zugehörige Reaktionen

1
Reaktionsaufzeichnung erstellen
Reaktionsgleichung von HRID 2243787
HRID 2243787als Produkt

Notizen zur Verbindung

Auf dieser SeiteGrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
Wasserlöslichkeit
Soluble
Merck
14 · 14,3438
InChI
InChI=1S/C11H14N4O4/c1-13-9-8(10(16)14(2)11(13)17)15(6-12-9)5-7-18-3-4-19-7/h6-7H,3-5H2,1-2H3
InChIKey
HWXIGFIVGWUZAO-UHFFFAOYSA-N
SMILES
N1(CC2OCCO2)C2=C(N(C)C(=O)N(C)C2=O)N=C1
CAS Datenbank
69975 · 69975-86-6(CAS DataBase Reference)
Biological Half-Life · 1 Eintrag

Following administration of a single intravenous dose of 100 mg over 10 minutes in adults with chronic bronchitis, the elimination half life of doxofylline was 1.83 ± 0.37 hours. Following oral administration of 400 mg twice daily for 5 days in adults with chronic bronchitis, the mean elimination half life was 7.01 ± 0.80 hours.

Metabolism/Metabolites · 1 Eintrag

Doxofylline is thought to undergo hepatic metabolism which accounts for 90% of total drug clearance. β-hydroxymethyltheophylline was detected in the serum and urine after oral administration of 400 mg given in healthy subjects. The circulating metabolite was devoid of any significant pharmacological activity.

MeSH Pharmacological Classification · 3 Einträge

Agents that suppress cough. They act centrally on the medullary cough center. EXPECTORANTS, also used in the treatment of cough, act locally.

Agents that cause an increase in the expansion of a bronchus or bronchial tubes.

Compounds which inhibit or antagonize the biosynthesis or actions of phosphodiesterases.

Absorption, Distribution and Excretion · 4 Einträge

After repeated administrations doxofylline reaches the steady-state in about 4 days. Following oral administration of 400 mg doxofylline twice daily for 5 days in adults with chronic bronchitis, the peak plasma concentrations (Cmax) at steady state ranged from 5.78 to 20.76 mcg/mL. The time to reach maximum concentration (Tmax) was 1.19 ± 0.19 hours. The absolute bioavailability of doxofylline in healthy subjects was 63 ± 25%.

Less than 4% of an orally administered dose is excreted unchanged in the urine due to extensive hepatic metabolism.

Doxofylline demonstrates a short distribution phase following intravenous administration of 100 mg given in adults with chronic bronchitis. As methylxanthines are distributed to all body compartments, doxofylline may be detected in breast milk and placenta.

Following oral administration of 400 mg doxofylline twice daily for 5 days, the total clearance was 555.2 ± 180.6 mL/min.

Anwendungen · 1 Eintrag

BeschreibungDoxofylline, a xanthine bronchodilator related to theophylline, is useful in the treatment of asthma and similar bronchospastic disorders. It has minimal activity on intestinal smooth muscle and the cardiovascular system, and is reportedly devoid of the behavioral effects of theophylline.

Vor- und nachgelagerte Produkte

Vorgelagerte Rohstoffe

Toluol-4-sulfonsureTheophyllinChlorhydrin2,4,6-Tris(chlormethyl)-1,3,5-trioxan2-(Chlormethyl)-1,3-dioxolan2-Brommethyl-1,3-dioxolanEthandiolNatriumhydroxidTetrabutylammomium bromideAceton